AVTXAvalo Therapeutics, Inc.

$13.43-0.37% 1Y

$13.43

$12.7452 weeks$22.87

The financials

Avalo Therapeutics, Inc. by the numbers

For the full year FY2025, revenue was $59K (−87% year on year) and net income −$78M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.

Avalo Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statement	Q2 2026	Q2 2025	Change
Operating income	−$32M	−$19M	n/a
Net income	−$36M	−$21M	n/a
Diluted EPS	−$0.83	−$1.92	n/a

Biotechnology

Ranks #43 of 196 by RyuScore

Compare peers

CADL-1.5%

Candel Therapeutics, Inc.

VSTM-1.8%

Verastem, Inc.

DSGN-1.8%

Design Therapeutics, Inc.

Olema Pharmaceuticals, Inc.